top of page
Browse by category
Search
GLP-1 medications for teens with type 2 diabetes and obesity frequently denied by insurance companies
Health insurance companies often deny coverage for GLP-1 receptor agonists (GLP1Ra) that treat children and teens with obesity and type 2...
Sex differences in how adipose tissue responds to insulin could explain why T2D is more prevalent in males
For Individuals who are living with obesity, adipose tissue insulin resistance is more severe in men than in women and may partly explain...
FLOW trial: Semaglutide 1.0mg demonstrates 24% reduction in the risk of kidney disease-related events in T2DM and chronic kidney disease patients
Headline results from the kidney outcomes trial FLOW (Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in...
Insulin-inhibitory receptor could be key to T2DM treatment
A novel study in mice with diet-induced obesity demonstrates that the knock-out of insulin-inhibitory receptor enhances glucose...
No overall cost–benefit after RYGB versus SG among T2DM patients
Patients with type 2 diabetes (T2DM) at baseline undergoing RYGB appear to experience a reduced need for ambulatory T2DM monitoring and...
Disrupted cellular function of “cleaning cells” may explain why some people with obesity develop T2DM
Disrupted function of “cleaning cells” in the body may help to explain why some people with obesity develop type 2 diabetes, while others...
GLP1 agonists associated with a reduced risk of developing cirrhosis and liver cancer in people with T2DM and chronic liver disease
Glucagon-like peptide-1 receptor (GLP1) agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people...
Increased body and abdominal fat cause insulin resistance in adolescents
High fat mass in adolescence causes insulin resistance, which can lead to a vicious cycle of worsening insulin resistance and obesity by...
Activating pathway promotes population of insulin-producing cells and enhances cells' function
Researchers at Weill Cornell Medicine have uncovered a novel route to stimulate the growth of healthy insulin-producing pancreatic beta...
T2DM diagnosis at age 30 can reduce life expectancy by up to 14 years
An individual diagnosed with type 2 diabetes at age 30 years could see their life expectancy fall by as much as 14 years, an...
Browse by tag
bottom of page